Promising cancer combo study halted early
Disease control
Terminated
This study tested a combination of two drugs, mirdametinib and BGB-3245, in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drugs could shrink tumors. The study was terminated early, so resul…
Phase: PHASE1, PHASE2 • Sponsor: SpringWorks Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 06:21 UTC